Lexamil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lexamil

Quick Facts

Property Description
Active ingredient Escitalopram (S-enantiomer)
Form Film-coated tablet; Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulating mood and anxiety states
Origin Synthetic chemical compound

What Type of Medicine is Lexamil?

Lexamil is the trade name for the prescription-only medication containing the active ingredient Escitalopram. It is formally classified as an Antidepressant medication belonging to the group of Selective Serotonin Reuptake Inhibitors (SSRIs). This classification means it is a synthetic psychotropic agent primarily intended to modulate chemical signaling in the central nervous system. The general therapeutic goal of this medication is to help stabilize and elevate mood, while also reducing the intensity of excessive worry or fear.

Escitalopram: Composition and Form

The active component in Lexamil is Escitalopram, typically formulated as Escitalopram oxalate. Escitalopram is recognized as a single-entity product and a synthetic chemical compound, distinguished as the pure, single S-enantiomer derivative of the older drug Citalopram. In terms of its pharmacological profile, the therapeutic action is concentrated within this single isomer. For oral administration, Lexamil is manufactured by Lundbeck as a film-coated tablet and an oral solution in some regions, providing formulation options for different patient groups.

The High Selectivity of Escitalopram

The primary action of Lexamil is defined by the compound's high selectivity for the serotonin neurotransmitter system. This specificity means Escitalopram works by inhibiting the neuronal reuptake of serotonin (5-HT) in the central nervous system, thereby enhancing the availability of this chemical messenger in the spaces between nerve cells. This targeted mechanism is intended to help restore communication within the brain pathways governing mood and emotional response, providing a pharmacological strategy for achieving emotional stability and functional improvement. This mechanism is characterized by its role in enhancing serotonergic activity without significantly impacting other neurotransmitter systems.

Regulatory References

  1. NIH MedlinePlus Drug Information on Escitalopram
  2. Escitalopram - StatPearls - NCBI Bookshelf

What side effects are possible with Lexamil?

Possible Side Effects and Safety Information

The official safety profile for Lexamil (Escitalopram) is structured around adverse reactions classified by frequency and grouped by the physiological system affected, based on regulatory documentation from authorities like the FDA and EMA.


Frequency-Classified Adverse Reactions

Adverse reactions are defined by their incidence observed in clinical trials:

Classification Example Adverse Reactions (Not Exhaustive)
Very Common (ge 1/10) Headache, Nausea
Common (ge 1/100 to <1/10) Insomnia, Somnolence, Increased sweating, Dizziness, Ejaculation disorder, Decreased libido

Reactions are grouped into System-Organ Classes, including Nervous System Disorders (e.g., somnolence) and Gastrointestinal Disorders (e.g., dry mouth, diarrhea). Most adverse reactions are documented as being most frequent during the first or second week of treatment and typically decrease with continued use.


Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight reactions of clinical significance. A Boxed Warning notes the increased risk of Suicidal Thoughts and Behaviors in children, adolescents, and young adults (up to age 24), requiring close monitoring during initial therapy or dose changes. Other serious documented risks include Serotonin Syndrome and QT Interval Prolongation, which can lead to ventricular arrhythmia (Torsade de pointes). Consequently, Lexamil is contraindicated in patients with known QT interval prolongation or congenital long QT syndrome. Hyponatremia (low sodium levels) is a documented risk, particularly in older adults.


Population-Specific Safety Notes

Specific caution is advised for older adults due to increased risks like hyponatremia. For use during pregnancy, warnings exist regarding potential symptoms of poor neonatal adaptation and a slight increase in the risk of postpartum hemorrhage.

Overdose and Emergency Response

Overdose and When to Seek Help

The information presented here is based exclusively on the official descriptions of overdose and the required emergency actions as documented in government regulatory sources.

Suspicion of an overdose with escitalopram, the active ingredient in Lexamil, mandates seeking immediate medical attention or contacting emergency services without delay, regardless of the severity of initial signs. Urgent help is required for all suspected cases due to the potential for delayed, severe complications.

Documented Overdose Manifestations

Official labeling indicates that overdose may present with Central Nervous System (CNS) effects such as dizziness, tremor, and somnolence. More severe manifestations include convulsions and coma. Gastrointestinal disturbances, including nausea and vomiting, are also documented. Cardiovascular signs can include tachycardia and hypotension.

Severe Outcomes and Management

Serious, life-threatening outcomes formally described include Serotonin Syndrome, which requires urgent medical intervention. The overdose also carries a risk of significant QT interval prolongation and associated cardiac arrhythmias. Due to these cardiovascular risks, prolonged continuous ECG monitoring in a hospital setting is required for management. The official guidance states that no specific antidote is known, and management is defined as providing symptomatic and supportive treatment.

Therapeutic Uses of Lexamil

What Lexamil Treats: Main Uses and Benefits

Lexamil is commonly used in conditions marked by severe mood disruption and pervasive anxiety states, targeting several core symptom clusters. It is used in the management of conditions involving heightened emotional tension, including Major Depressive Disorder (MDD) and anxiety conditions such as Generalized Anxiety Disorder (GAD), Panic Disorder, Social Anxiety Disorder, and Obsessive-Compulsive Disorder (OCD). The medication is indicated for these conditions.

It is applied in clinical settings where patients experience overwhelming, chronic excessive worry and tension, or debilitating loss of pleasure (anhedonia). It helps ease the intensity of these manifestations, providing supportive relief. This symptomatic support is used for managing pervasive apprehension and physical restlessness, which helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Mood & Anxiety
Core Function Provides support that helps ease the overall symptom burden of major depressive and chronic anxiety states.
Clinical Context Often used during phases when symptoms intensify and supportive relief is appropriate.
Key Symptom Areas Persistent low mood, excessive worry, recurrent panic attacks, and obsessive thoughts.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lexamil?

Lexamil (Escitalopram) use is governed by specific eligibility rules established in official regulatory documents from authorities such as the FDA and EMA.


Absolute Contraindications

Use is strictly prohibited for patients with known hypersensitivity to Escitalopram, Citalopram, or any excipients. It is also contraindicated in patients with known QT interval prolongation or congenital long QT syndrome. The medicine must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid or intravenous Methylene Blue, or with the drug Pimozide.


Age- and Condition-Based Restrictions

Population Group Regulatory Status
Adults Approved for established indications.
Adolescents (12+) Approved for Major Depressive Disorder.
Children (Under 7) Use is not approved for any indication.
Older Adults Use permitted, but lower maximum dose recommended.

Use requires caution and often a restricted maximum dose for patients with hepatic (liver) impairment and those with severe renal (kidney) impairment. Caution is also required in individuals with a history of seizures or a history of mania/hypomania. Use during pregnancy and lactation is conditional, permissible only if the regulatory-documented potential benefit is determined to justify the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents outline specific interaction patterns for Lexamil (Escitalopram) that necessitate restrictions on co-administration.

Contraindicated Combinations and Timing Rules

Lexamil is formally contraindicated for co-administration with Monoamine Oxidase Inhibitors (MAOIs), including psychiatric MAOIs, the antibiotic Linezolid, and Intravenous Methylene Blue, due to the risk of Serotonin Syndrome. Co-administration with Pimozide is also contraindicated. A mandatory 14-day separation period must be observed when switching between Lexamil and a psychiatric MAOI. Certain regulatory agencies also advise caution or restriction with medicinal products known to prolong the QT interval.


Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type Interacting Substance/Class Official Documented Outcome
Pharmacodynamic Other Serotonergic Agents (e.g., Triptans, Tramadol, St. John's Wort) Increased risk of Serotonin Syndrome
Pharmacodynamic Drugs that Interfere with Hemostasis (e.g., NSAIDs, Warfarin) Increased risk of Abnormal Bleeding
Pharmacokinetic CYP2D6 Substrates (e.g., Desipramine, Metoprolol) Escitalopram's weak inhibition of CYP2D6 results in increased exposure (AUC) of the co-administered drug

Co-administration with inhibitors of CYP2C19 (such as Omeprazole or Cimetidine) may increase the plasma concentration of Escitalopram. The manufacturer advises officially to avoid the consumption of alcohol during treatment. The risk of interaction may be heightened in populations with hepatic impairment, as noted in regulatory cautions regarding altered drug metabolism.

Mechanism of Action

Lexamil, which contains escitalopram, functions as a selective serotonin reuptake inhibitor (SSRI) and primarily targets the Serotonin Transporter (SERT), a protein located on the presynaptic membrane of central nervous system (CNS) serotonergic neurons.

Escitalopram acts as an inhibitor of SERT by binding to both the orthosteric (primary) and an allosteric (secondary) site on the transporter. This dual-site interaction prevents the reuptake of the neurotransmitter serotonin (5-HT) from the synaptic cleft back into the presynaptic neuron. Consequently, the concentration of 5-HT is elevated and sustained within the synaptic cleft.

This increased synaptic 5-HT availability leads to enhanced and prolonged stimulation of postsynaptic 5-HT receptors. Over time (weeks), the chronic elevation of 5-HT induces an intracellular cascade, including the desensitization and downregulation of presynaptic 5-HT1A autoreceptors and possible modulation of neurotrophic factors like Brain-Derived Neurotrophic Factor (BDNF). The system-level physiological consequence of this sustained serotonergic potentiation is the modulation of neural signaling across the brain, including regions involved in emotional and regulatory processes.

Dosage and Administration Information

How Lexamil is Used: Administration and Usage Overview

Lexamil (escitalopram) is administered through the oral route, available as a film-coated tablet and an oral solution in some regions. The medication is typically taken once daily, either in the morning or the evening, and its intake is not dependent on food; it can be taken with or without a meal.

Standard Dosing Principles

The treatment protocol involves specific dose management. For most adult indications, the typical starting dose is 10 mg once daily. The dosage may be adjusted up to a maximum of 20 mg daily, and such adjustments generally occur after a minimum of one week of treatment. The dose used for long-term maintenance treatment is usually continued for at least six months to help consolidate the therapeutic effect.

Population-Specific Use and Discontinuation

Specific dosage limits are defined for certain patient groups. For older adults (geriatric) and individuals with hepatic impairment, the maximum recommended daily dose is typically 10 mg. Standard protocols also include information for pediatric use, with a 10 mg once daily dose described for adolescents (12+) with Major Depressive Disorder and children (7+) with Generalized Anxiety Disorder. A standard clinical protocol is that abrupt discontinuation is avoided; the dose is gradually reduced (tapered) over a period of at least one to two weeks, or longer, when treatment is stopped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lexamil

Research evidence for Lexamil (escitalopram) has been collected from numerous short-term and long-term studies. These investigations contribute to the broader evidence landscape used to characterize the compound. This summary describes the type of evidence available, the outcomes measured, and the recognized limitations, without offering any clinical advice or interpretation of the findings.


Evidence for use in Major Depressive Disorder (MDD)

The research explored symptom patterns in MDD and involved short-term controlled Randomized Trials (RCTs). These studies were evaluated in adult populations and, in some cases, adolescent individuals. Researchers described patterns related to the measured change in symptom scores between the active compound group and the inactive control group, including measurements related to symptom variability (response) and achieving minimal symptom activity (remission).

Comparative evidence is lacking across all available therapeutic compounds. While research provides insight into short-term changes, the full spectrum of long-term outcomes related to functional recovery are not fully established.


Evidence for use in Generalized Anxiety Disorder (GAD)

The evidence for GAD was examined in a combination of short-term trials and subsequent long-duration studies. Findings indicate patterns related to the return of heightened symptoms (relapse) when continued observation was compared to an inactive control. Data for certain complex patient groups remain insufficient, as most results apply only to the specific populations studied in the trials.


Long-term Follow-up and Specific Populations

Long-term maintenance studies tracked individuals who had already shown initial measured changes, with studies monitoring the durability of the observed changes and the time until the recurrence of symptoms. The research does not provide individual predictions regarding long-term response beyond the trial periods.

Research was also evaluated in adolescents with MDD and GAD, and in older adults. Findings were mixed in some adolescent studies compared to adult trials. Differences may exist in how the compound is handled physiologically in older adults, which can influence measured outcomes. Subgroup findings are uncertain due to smaller sample sizes.

Key Studies & References Depression in adults: treatment and management (NICE Guideline NG222)

Frequently Asked Questions (FAQ)

Common questions about Lexamil (FAQ)

Q: What is the risk of dependence or withdrawal symptoms associated with Lexamil?

Official documents and patient information clarify that this medication is not described as addictive. However, abrupt discontinuation is warned against due to the risk of experiencing discontinuation symptoms. When treatment is stopped, official documents describe a procedure involving a gradual reduction of the dose over time.


Q: How quickly can someone expect to feel the effects of Lexamil?

According to official prescribing information, it typically takes several weeks before a patient begins to feel measurable improvement in symptoms. Achieving the full therapeutic benefit may require even longer. This timeframe highlights the importance of sustained therapy.


Q: Is there a typical timeframe before the full effect of Lexamil is observed?

Official information indicates that it may take several weeks for the full benefits of the medication to be observed. The labeling describes the need for continued, sustained therapy even if initial changes are not immediately noticed.


Q: What is the general expectation for how long Lexamil treatment lasts?

Regulatory documents suggest that for acute episodes of Major Depressive Disorder, treatment typically involves several months or longer of sustained pharmacological therapy. This is done to help consolidate the initial improvements observed.


Q: What are the official recommendations for stopping Lexamil treatment?

Official guidance emphasizes that treatment should never be stopped suddenly. When discontinuing, a gradual dose reduction (tapering) is described in the documents. Official guidance notes that the process of discontinuation is managed and directed by a prescribing healthcare provider.


Q: How is Lexamil different from other common medications in its class?

Official descriptions note that Lexamil is the single, purified S-enantiomer of Citalopram, which is its precursor. This refinement is described in documents as resulting in a highly selective action that is concentrated within this single isomer.


Q: Do studies compare Lexamil's effects to other similar medicines?

Research and clinical studies have been conducted to compare Lexamil to its precursor compound, citalopram, in terms of measured efficacy metrics. However, official research summaries note that comparative evidence is generally lacking across all available therapeutic compounds.


Q: What should be done if someone misses a scheduled dose of Lexamil?

Patient information states that if a dose is missed, it should be taken as soon as possible. However, if it is close to the time for the next scheduled dose, the missed dose should be skipped entirely. Patients are cautioned against taking double doses.


Q: If someone feels better, should they stop taking Lexamil?

Official information indicates that continued therapy is often necessary to prevent the return of symptoms. The decision to stop treatment is managed by a prescribing healthcare provider.


Q: How are potential side effects of Lexamil managed according to official information?

Official patient information often provides coping strategies for common adverse reactions. For instance, taking the medication with food may help manage nausea, or adjusting the time of day it is taken might help address drowsiness.


Q: Does Lexamil cause weight gain, according to research evidence?

Weight gain is listed as an adverse reaction that has been reported in clinical trial data with the use of this medication. This finding is included in the official safety profile based on research evidence.


Q: What are specific food or drink interactions mentioned for Lexamil?

Regulatory documents state that alcohol consumption should be avoided during treatment. No specific food interactions, beyond general statements about taking it with or without food, are typically highlighted.


Q: Can Lexamil be taken with over-the-counter pain relievers?

Official information indicates that co-administration with certain nonprescription pain relievers, such as NSAIDs (like ibuprofen or naproxen) or aspirin, may be associated with an increased risk of abnormal bleeding.


Q: Is it safe to use Lexamil with supplements or herbal products?

The herbal remedy St. John’s Wort should not be taken with this medication due to interaction risks. Official sources indicate that the use of any supplements or herbal products requires review by a healthcare provider.


Q: What are the known interactions between Lexamil and alcohol?

Official warnings state that alcohol can increase the central nervous system side effects of Lexamil, such as dizziness and drowsiness. Combining them may also affect thinking and judgment.


Q: Is Lexamil use described in official documents for use during pregnancy or breastfeeding?

Use during pregnancy and breastfeeding is described as conditional in official documents. It is only permitted if the potential benefit is determined to justify the potential risk, which is a decision managed and reviewed by a healthcare provider.


Q: Does Lexamil affect blood pressure levels, according to regulatory data?

Regulatory information regarding this class of medication (SSRIs) suggests that blood pressure monitoring may be necessary during treatment. This is because these compounds may, in some cases, affect blood pressure levels.


Q: Why do some people report feeling less effective after taking Lexamil for a long time?

Scientific literature has examined the potential for the body to undergo neuroadaptation over time. This process may lead to what users describe as tolerance or a perceived loss of effectiveness, sometimes referred to as 'poop-out,' in some individuals.


Q: Are there different forms (tablet, liquid) of Lexamil available?

According to official prescribing information, the medication is available as both a film-coated tablet and an oral solution (oral drops) in certain regions.


Q: How does Lexamil interact with medications for migraine headaches?

Co-administration with Triptans, which is a common class of medication used for migraine headaches, may increase the risk of Serotonin Syndrome. This is due to the combined serotonergic activity of both drugs.


Q: What is the risk of bleeding or bruising mentioned with Lexamil?

Abnormal bleeding or bruising is a recognized adverse reaction described in the official safety profile of this medication. This risk is increased when used alongside other medications that affect blood clotting.


Q: What is the information regarding Lexamil and sexual side effects?

Sexual side effects, such as decreased sexual drive and problems with ejaculation or orgasm, are documented as potential adverse reactions. Official information notes that in rare cases, these effects may be long-lasting even after stopping treatment.


Q: Does the efficacy of Lexamil vary by patient characteristics?

Research evidence has indicated that the measured efficacy may differ depending on the degree of severity of depression. Additionally, studies have noted mixed findings or physiological differences in specific populations like adolescents and older adults.


Q: What common misunderstandings exist about how Lexamil works?

Official patient information is designed to clarify common misconceptions about the medication. For example, documents state clearly that the medication is not known to be addictive.


Q: What is the potential impact of Lexamil on liver function tests?

The medication is generally used with caution in patients with hepatic (liver) impairment. Post-market surveillance programs have examined the potential for liver-related issues, noting that the probability of drug-induced liver injury is low.

How should Lexamil be stored and disposed of?

Lexamil (escitalopram) must be stored under specific environmental constraints to maintain product stability and must be handled according to official disposal rules.

Storage Conditions

The medicine should be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C (86 F). The product must be protected from moisture and excessive heat and should be kept in the original container, which must be closed tightly.

Shelf-Life and Disposal

The oral solution formulation has a specific use-limit: it must be discarded 8 weeks after the first opening. Lexamil and all medicines must be kept out of the reach and sight of children.

Unused or expired product should be disposed of in accordance with local regulatory requirements for pharmaceutical waste, often by taking it to a pharmacy or drug collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lexamil found in:

A-Z Index: